<DOC>
	<DOC>NCT03069001</DOC>
	<brief_summary>This prospective study was conducted at Ain Shams University Hospital, Internal Medicine, Hepatology and Gastroenterology Department, and Tropical Medicine Department. To compare the efficacy of the combination of sofosbuvir and simeprevir for 12 weeks with the combination of sofosbuvir and ribavirin for 24 weeks in Egyptian patients with HCV-related Child A cirrhosis.</brief_summary>
	<brief_title>Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV</brief_title>
	<detailed_description />
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Patients with chronic HCV infection with a positive HCV RNA level by PCR. Total bilirubin &gt; 2 mg/dl. serum albumin &lt; 2.8 g/dl. INR &gt; 1.7. platelet count &lt; 50000/mm3. serum creatinine &gt; 2.5 mg/dl. patients presented by ascites or hepatic encephalopathy. patients with evidence of other causes of liver diseases, including hepatitis A, hepatitis B, autoimmune hepatitis, alcoholic liver disease, druginduced hepatitis, haemochromatosis, Wilson disease or alpha1 antitrypsin deficiency. patients with any advanced systemic disease. pregnancy or inability to use effective contraception in females.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HCV treatment</keyword>
</DOC>